Aiqin Zhang

Zhejiang Cancer Hospital, Hang-hsien, Zhejiang Sheng, China

Are you Aiqin Zhang?

Claim your profile

Publications (3)4.23 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Recently, polymorphisms in COMT (catechol-O-methyltransferase), PLCH1 (phosphoinositide-specific phospholipase C eta 1), and CYP17A1 (cytochrome P450 17A1) were found to be associated with the development of lung cancer in a non-Chinese population. AIMS: To explore the potential association between single-nucleotide polymorphism (SNP) in COMT, PLCH1, CYP17A1, and non-small-cell lung cancer (NSCLC) susceptibility in Chinese patients who were nonsmokers. METHODS: A case-controlled study was conducted in 200 patients with NSCLC and 200 healthy controls who were age and sex matched. SNPs rs4680, rs181696, and rs743572 from the COMT, PLCH1, and CYP17A1 genes, respectively, were selected for genotyping. The association between genotype and lung cancer risk was evaluated by computing the odds ratio and 95% confidence interval from multivariate unconditional logistic regression analyses with adjustment for sex and age. RESULTS: The frequency of the G genotype in COMT rs4680 was statistically different between patients with NSCLC and controls (P = .04), and between patients with adenocarcinomas (ADC) and controls (P = .02). The frequency of the A genotype in PLCH1 rs181696 occurred more frequently in squamous cell carcinomas (SQC) than in controls (P = .02). The G/G homozygous genotype in COMT rs4680 and A/A homozygous genotype in PLCH1 rs181696 were associated with ADC and SQC, respectively (odds ratio [OR] 0.61 and OR 2.01, respectively). CONCLUSION: In this study, we found that the COMT rs4680 SNP was significantly associated with a reduced risk of NSCLC, especially ADC, which suggests that this SNP may have a protective effect. Moreover, the PLCH1 rs181696 SNP was strongly associated with an increased risk of SQC, which suggests that this SNP may be a risk factor for developing SQC.
    Clinical Lung Cancer 05/2012; · 2.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, two genome-wide association studies in Asia identified gene polymorphisms known as rs4488809, rs9816619 in TP63 and rs2131877, rs952481 in C3orf21. It has been proposed that these polymorphisms are susceptibility loci for non-small cell lung cancer (NSCLC) development among Japanese and Korean populations. We ask whether susceptibility to NSCLC is limited to the Chinese population or whether the environment also affects genetic polymorphisms. We conducted a matched case-control study to explore this question. Results show that polymorphism of TP63 was not associated with NSCLC development, whereas variant genotypes of C3orf21 were nominally associated with a reduced risk of lung adenocarcinoma (OR=0.619, 95% CI=0.390-0.976). These results strongly suggest that environmental agents interact with human genetic polymorphism independent of ethnic background. In addition, the C3orf21 gene may be a potential susceptibility marker for lung adenocarcinoma independent of ethnic background and environmental agents.
    Gene 04/2012; 497(1):93-7. · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveThe aim of this study was to observe and compare the antiemetic effectiveness and adverse events of magnetotherapy plus 5-hydroxytryptamine (5-HT3) receptor inhibitor granisetron hydrochloride vs granisetron hydrochloride alone in patients with chemotherapy. MethodsSixty-four patients were randomized to receive either granisetron hydrochloride alone (control group: granisetron hydrochloride 3 mg intervenous infusion before chemotherapy, from the 1st day of chemotherapy course until the day after chemotherapy course completed) or magnetotherapy plus granisetron hydrochloride (treatment group: the same granisetron hydrochloride regimen plus rotatory magnetotherapy of 1 every day after chemotherapy for 5 begin with chemotherapy). Baseline characteristics were similar in both groups. The patients’ emesia was evaluated according to WHO’s criteria. The density of 5-HT3 was detected by enzyme-linked immunosorbent assay (ELISA). ResultsIn the treatment of acute vomiting, there was no significant difference between two groups (P > 0.05), but in the treatment of tardive vomiting, the effectiveness in treatment group was better than that in control group (P < 0.05). The density of 5-HT3 in treatment group and control group were (225.32 ± 57.29) ng/mL vs (213.00 ± 53.29) ng/mL before chemotherapy and (273.88 ± 75.42) ng/mL vs (313.17 ± 76.36) ng/mL after chemotherapy (P < 0.01); the rate of adverse events was 36.36% and 48.39% respectively in treatment group and control group (P > 0.05). ConclusionMagnetotherapy plus granisetron hydrochloride provide better effectiveness than granisetron hydrochloride alone, and both therapies have synergistic effect. The adverse events didn’t raised in treatment group. Key wordsmagnetotherapy-5-hydroxytryptamine (5-HT3) receptor inhibitor-chemotherapy-vomiting
    The Chinese-German Journal of Clinical Oncology 09/2010; 9(9):543-546.